Skip to content
Screener

Moderna MRNA Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$167M-46.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$816.54M+83.1%
Pfizer logo
PfizerPFE
——
ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$145.0M+2.1%
Gross profit$52.0M+126%
Operating income-$815.0M+10.1%
Net income-$782.0M+5.2%
EPS (diluted)-$1.97+7.5%

Balance sheet

See full
Cash & equivalents$1.7B+34.5%
Total debt$1.2B+60.8%
Total equity$6.8B-28.1%
Total assets$11.0B-8.7%

Cash flow

See full
Operating cash flow-$526.0M+42.8%
CapEx$37.0M+1,133%
Free cash flow-$563.0M+38.9%

Valuation

See full
Market cap$22.46B+116%
Enterprise value$21.97B+122%
P/S10.1×+6.7×

Profitability

See full
Gross margin23.4%-29.1pp
Operating margin-149%+99.9pp
Net margin-141.4%+141pp
FCF margin-132.4%—

Returns & leverage

See full
Return on equity-39%+28.0pp
Debt / equity0.2×+0.1×
Current ratio2.3×-1.6×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: Moderna’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001682852-26-000060
Line itemMarch 31, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$1,908$2,595
Investments3,2973,204
Accounts receivable, net71184
Inventory146153
Prepaid expenses and other current assets348408
Total current assets5,7706,544

Item 1. Financial Statements (Unaudited)

FAQ

What is Moderna's available for sale securities debt securities current?
Moderna (MRNA) reported available for sale securities debt securities current of $3.3B in Q1 2026.
How has Moderna's available for sale securities debt securities current changed year-over-year?
Moderna's available for sale securities debt securities current decreased by 24.2% year-over-year, from $4.35B to $3.3B.
What is the long-term trend for Moderna's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Moderna's available for sale securities debt securities current has grown at a 10.1% compound annual growth rate (CAGR), from $1.98B to $3.2B.

Ask your AI about Moderna's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude